Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.

Christian ThomasMaximilian P BrandtStephanie BaldaufIgor TsaurSebastian FreesHendrik BorgmannWolfgang JägerGeorg BartschMeike SchneiderRobert DotzauerAndreas NeisiusAxel Haferkamp

Published in: International urology and nephrology (2018)

Despite novel hormonal drugs, docetaxel still plays an important role in the treatment of mCRPC. Patients with partial-PSA-response at rechallenge or a treatment-free interval > 3 m benefit most from docetaxel re-exposure.

Keyphrases

prostate cancer
type diabetes
combination therapy
adipose tissue
radical prostatectomy